Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis

2007 ◽  
Vol 27 (11) ◽  
pp. 1063-1069 ◽  
Author(s):  
Manathip Osiri ◽  
Pirom Kamolratanakul ◽  
Andreas Maetzel ◽  
Peter Tugwell
Keyword(s):  
Rheumatoid Arthritis ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Effectiveness Analysis ◽  
Disease Modifying

Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

2011 ◽  
Vol 13 (5) ◽  
pp. 381-382
Author(s):  
Aarat M. Patel ◽  
Daniel Lupash ◽  
Douglas Chew ◽  
Marc C. Levesque ◽  
Larry W. Moreland
Keyword(s):  
Rheumatoid Arthritis ◽  
Cost Effectiveness ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

scholarly journals Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Maurizio Benucci ◽  
Gianantonio Saviola ◽  
Mariangela Manfredi ◽  
Piercarlo Sarzi-Puttini ◽  
Fabiola Atzeni
Keyword(s):  
Rheumatoid Arthritis ◽  
Cost Effectiveness ◽  
Disease Activity ◽  
Disease Onset ◽  
Critical Evaluation ◽  
Joint Damage ◽  
Review Literature ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

The cost effectiveness of treatments that have changed the “natural history” of a chronic progressive disease needs to be evaluated over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA) and should be started as early as possible. A number of studies have shown that they are effective in improving disease activity and function, and in joint damage. Our review was focused on revision and critical evaluation of the studies including the literature on cost effectiveness of DMARDs (cyclosporine A, sulphasalazine, leflunomide, and methotrexate). The European League Against Rheumatism (EULAR) recommendations showed that traditional DMARDs are cost effective at the time of disease onset. They are less expensive than biological DMARDs and can be useful in controlling disease activity in early RA.

Sign in / Sign up

Export Citation Format

Share Document